Top Abstract Purchase Related
Home
>
Node
>
Subnode

Advantages of direct thrombin inhibition in high- and low-risk patients

Stone, G.W.

Journal of Invasive Cardiology 16 Suppl G: 12-17

2004

ISSN/ISBN: 1042-3931
PMID: 23570203
Document Number: 571043
For an anticoagulant to replace heparin (and possibly glycoprotein IIb/IIIa inhibitors) for the interventional cardiologist, it must be proven to be useful in preventing ischemic complications and minimize bleeding risk in low- and high-risk patients in the settings of percutaneous coronary interventions (PCI), acute coronary syndromes (ACS) and acute myocardial infarction (AMI). The optimal agent will also streamline care and be cost effective. Bivalirudin has desirable pharmacokinetic properties and has been shown to improve outcomes as an alternative to heparin and glycoprotein IIb/IIIa inhibitors in both high- and low-risk patients undergoing urgent and elective PCI. Ongoing studies are investigating the utility of this agent in patients with ACS and AMI.

Document emailed within 1 workday
Secure & encrypted payments

Momi, S.; Nasimi, M.; Colucci, M.; Nenci, G.G.; Gresele, P. 2001: Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition Haematologica 86(3): 297-302
Gandossi, E.; Lunven, C.; Gauffeny, C.; Roome, N.O.; Berry, C.N. 1998: Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors Thrombosis and Haemostasis 80(5): 840-844
Hermanides, R.S.; Ottervanger, J.P.; ten Berg, J.M.; Gosselink, A.T.M.; van Houwelingen, G.; Dambrink, J.-H.E.; Stella, P.R.; Hamm, C.; van 't Hof, A.W.J. 2012: Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score Journal of Invasive Cardiology 24(3): 84-89
Lednitskiĭ, D.G. 1977: Model studies of lateral inhibition as a mechanism of detecting motion. I. Analytic consideration of direct inhibition Biofizika 22(1): 127-132
Verstraete, M. 1997: Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance Thrombosis and Haemostasis 78(1): 357-363
Vakharia, D.D.; Rao, S.S. 1978: Serum HPL in normal and high risk pregnancy by haemagglutination inhibition test Indian Journal of Medical Research 68: 272-278
von Felten, A. 1992: Prevention of venous thromboembolism with heparin in risk patients during pregnancy: monitoring by measuring thrombin-antithrombin III complex Therapeutische Umschau. Revue Therapeutique 49(12): 837-842
Adem, C.; Jenkins, R.B.; Capron, Fédérique.; Stoppa-Lyonnet, D. 2004: High-risk lesions in high-risk women: a high-risk formalin-based biology! Journal of clinical oncology: official journal of the American Society of Clinical Oncology 22(6): 1159-61; author reply 1161-2
Hanada, N.; Tanaka, S.; Takahata, T.; Sato, A. 2014: Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(6): 702-706
Shani, A.; Rozen, P.; Fink, A.; Bass, D.; Fraser, D.; Bentwich, Z. 1989: Limited value of leukocyte adherence inhibition in screening for colorectal neoplasia in high-risk groups Cancer Detection and Prevention 13(5-6): 311-316
Nydahl, S.; Frebelius, S.; Swedenborg, J. 1993: Effect of heparin on thrombin inhibition in the microcirculation Thrombosis and Haemostasis 69(1): 41-44
Kirchhof, B. 1984: Methodologic studies of the activation and inhibition of thrombin Fortschritte der Medizin 102(41): 1056-1058
Chen, L.; Nichols, W.W.; Mattsson, C.; Teger-Nilsson, A.C.; Saldeen, T.G.; Mehta, J.L. 1996: Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis Journal of Pharmacology and Experimental Therapeutics 277(3): 1276-1283
Prasa, D.; Svendsen, L.; Stürzebecher, J. 1997: Inhibition of thrombin generation in plasma by inhibitors of factor Xa Thrombosis and Haemostasis 78(4): 1215-1220
Comar, M.; Spano, A.; Canova, S.; Bogoni, S.; Marziliano, N.; Cernigoi, E.; Boniotto, M.; Amoroso, A.; Parodi, S.; Campello, C.; Crovella, S. 2001: Direct in situ PCR allows rapid and sensitive detection of high risk human papillomavirus in cytologic specimens and formalin-fixed paraffin tissues by fluorescent labelling International Journal of Oncology 18(1): 181-185
Yang, W.X. 1992: Exposure level of N-nitrosamines in the gastric juice and its inhibition by vitamin C in high risk areas of esophageal cancer Zhonghua Zhong Liu Za Zhi 14(6): 407-410
Brill-Edwards, P.; Van Ryn-McKenna, J.; Cai, L.; Ofosu, F.A.; Buchanan, M.R. 1992: Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy Thrombosis and Haemostasis 68(4): 424-427
Vogel, C.N.; Kingdon, H.S.; Lundblad, R.L. 1979: Correlation of in vivo and in vitro inhibition of thrombin by plasma inhibitors Journal of Laboratory and Clinical Medicine 93(4): 661-673
Jonasch, E.; Kumar, U.N.; Linette, G.P.; Hodi, F.S.; Soiffer, R.J.; Ryan, B.F.; Sober, A.J.; Mihm, M.C.; Tsao, H.; Langley, R.G.; Cosimi, B.A.; Gadd, M.A.; Tanabe, K.K.; Souba, W.; Haynes, H.A.; Barnhill, R.; Osteen, R.; Haluska, F.G. 2000: Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma Cancer Journal 6(3): 139-145
Pickardt, C.R.; Bauer, M.; Horn, K.; Kubiczek, T.; Scriba, P.C. 1977: Advantages of direct determination of thyroxine binding globulin (TBG) in diagnosis of thyroid gland function Der Internist 18(10): 538-543